Literature DB >> 8791591

CD40 ligand-dependent T cell activation: requirement of B7-CD28 signaling through CD40.

Y Yang1, J M Wilson.   

Abstract

The role of CD40 ligand (CD40L) in the primary activation of T cells is not clear. The cellular and humoral immune responses to adenoviral vectors in a murine model of liver-directed gene transfer were studied to define the mechanisms responsible for CD40L-dependent T cell priming. CD40L-deficient mice did not develop effective cytotoxic T cells to transduced hepatocytes, and T cell-dependent B cell responses were absent. Full reconstitution of cellular and humoral immunity was achieved in CD40L-deficient mice by administration of an activating antibody to CD40 that increased expression of B7.2 on spleen cells. Wild-type mice could be made nonresponsive to vector by administration of antibodies to B7. Thus, CD40L-dependent activation of T cells occurs through signaling of CD40 in the antigen-presenting cell to enhance requisite costimulatory pathways that include B7.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8791591     DOI: 10.1126/science.273.5283.1862

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  83 in total

1.  Cognate stimulatory B-cell-T-cell interactions are critical for T-cell help recruited by glycoconjugate vaccines.

Authors:  H K Guttormsen; A H Sharpe; A K Chandraker; A K Brigtsen; M H Sayegh; D L Kasper
Journal:  Infect Immun       Date:  1999-12       Impact factor: 3.441

2.  Implication of interfering antibody formation and apoptosis as two different mechanisms leading to variable duration of adenovirus-mediated transgene expression in immune-competent mice.

Authors:  D B Schowalter; C L Himeda; B L Winther; C B Wilson; M A Kay
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

3.  Association of B7-1 co-stimulation with the development of graft arterial disease. Studies using mice lacking B7-1, B7-2, or B7-1/B7-2.

Authors:  Y Furukawa; D A Mandelbrot; P Libby; A H Sharpe; R N Mitchell
Journal:  Am J Pathol       Date:  2000-08       Impact factor: 4.307

4.  New insights into the interactions between T-cell costimulatory blockade and conventional immunosuppressive drugs.

Authors:  Masayuki Sho; Sigrid E Sandner; Nader Najafian; Alan D Salama; Victor Dong; Akira Yamada; Koji Kishimoto; Hiroshi Harada; Isabela Schmitt; Mohamed H Sayegh
Journal:  Ann Surg       Date:  2002-11       Impact factor: 12.969

5.  CD40 ligand-dependent activation of cytotoxic T lymphocytes by adeno-associated virus vectors in vivo: role of immature dendritic cells.

Authors:  Y Zhang; N Chirmule; G p Gao; J Wilson
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

6.  CD45 opposes beta-amyloid peptide-induced microglial activation via inhibition of p44/42 mitogen-activated protein kinase.

Authors:  J Tan; T Town; T Mori; Y Wu; M Saxe; F Crawford; M Mullan
Journal:  J Neurosci       Date:  2000-10-15       Impact factor: 6.167

7.  STAT3 Knockdown in B16 Melanoma by siRNA Lipopolyplexes Induces Bystander Immune Response In Vitro and In Vivo.

Authors:  Aws Alshamsan; Samar Hamdy; Azita Haddadi; John Samuel; Ayman O S El-Kadi; Hasan Uludağ; Afsaneh Lavasanifar
Journal:  Transl Oncol       Date:  2011-06-01       Impact factor: 4.243

Review 8.  Effector lymphocytes in islet cell autoimmunity.

Authors:  Pere Santamaria
Journal:  Rev Endocr Metab Disord       Date:  2003-09       Impact factor: 6.514

9.  Longitudinal requirement for CD4+ T cell help for adenovirus vector-elicited CD8+ T cell responses.

Authors:  Nicholas M Provine; Rafael A Larocca; Pablo Penaloza-MacMaster; Erica N Borducchi; Anna McNally; Lily R Parenteau; David R Kaufman; Dan H Barouch
Journal:  J Immunol       Date:  2014-04-28       Impact factor: 5.422

10.  Central nervous system toxoplasmosis with an increased proportion of circulating gamma delta T cells in a patient with hyper-IgM syndrome.

Authors:  L E Leiva; J Junprasert; D Hollenbaugh; R U Sorensen
Journal:  J Clin Immunol       Date:  1998-07       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.